$INGN
Inogen Inc Stock $ingn

$ingn Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156459021008106 Filed on February 24, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$73.98M	$74.33M	$71.69M
YoY Change	-6.26%	-19.0%	-29.06%
Cost Of Revenue	$39.90M	$41.30M	$38.90M
YoY Change	-11.33%	-14.67%	-23.5%
Gross Profit	$34.06M	$33.01M	$32.75M
YoY Change	0.4%	-23.8%	-34.78%
Gross Profit Margin	46.04%	44.41%	45.68%
Selling, General & Admin	$35.90M	$31.80M	$32.40M
YoY Change	0.84%	-2.37%	-11.48%
% of Gross Profit	105.41%	96.35%	98.93%
Research & Development	$3.700M	$3.500M	$3.300M
YoY Change	2.78%	32.78%	120.0%
% of Gross Profit	10.86%	10.6%	10.08%
Depreciation & Amortization	$4.930M	$4.710M	$4.480M
YoY Change	6.94%	28.34%	62.32%
% of Gross Profit	14.47%	14.27%	13.68%
Operating Expenses	$39.60M	$35.30M	$35.70M
YoY Change	1.02%	0.26%	-6.3%
Operating Profit	-$5.541M	-$2.294M	-$2.951M
YoY Change	4.98%	-128.3%	-124.36%
Interest Expense	$100.0K	$100.0K	$200.0K
YoY Change	-87.5%	-90.91%	-85.71%
% of Operating Profit
Other Income/Expense, Net	$300.0K	$200.0K	$100.0K
YoY Change	50.0%	-139.76%	-93.5%
Pretax Income	-$5.205M	-$1.913M	$3.525M
YoY Change	22.85%	-121.86%	-74.24%
Income Tax	-$84.00K	-$214.0K	$945.0K
% Of Pretax Income			26.81%
Net Earnings	-$5.121M	-$1.699M	$2.580M
YoY Change	272.44%	-124.76%	-74.61%
Net Earnings / Revenue	-6.92%	-2.29%	3.6%
Basic Earnings Per Share	-$0.23	-$0.08	$0.12
Diluted Earnings Per Share	-$0.23	-$0.08	$0.12
COMMON SHARES
Basic Shares Outstanding	22.04M	22.00M	21.96M
Diluted Shares Outstanding	22.04M	22.00M	22.22M

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$231.2M	$220.5M	$218.6M
YoY Change	10.58%	9.9%	-14.65%
Cash & Equivalents	$212.0M	$214.0M	$214.1M
Short-Term Investments	$19.26M	$6.525M	$4.549M
Other Short-Term Assets	$17.90M	$18.90M	$16.50M
YoY Change	75.49%	70.27%	54.21%
Inventory	$24.82M	$29.22M	$36.18M
Prepaid Expenses
Receivables	$29.72M	$31.69M	$28.42M
Other Receivables	$2.100M	$3.100M	$3.000M
Total Short-Term Assets	$305.7M	$303.4M	$302.8M
YoY Change	4.61%	4.68%	-11.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.23M	$25.32M	$21.53M
YoY Change	45.23%	27.31%	0.79%
Goodwill	$33.17M	$33.05M	$32.96M
YoY Change	0.64%	-0.67%	1369.98%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.669M	$18.20M	$18.20M
YoY Change	-45.4%	290.22%	279.72%
Total Long-Term Assets	$156.2M	$156.9M	$155.3M
YoY Change	0.67%	1.29%	146.32%
TOTAL ASSETS
Total Short-Term Assets	$305.7M	$303.4M	$302.8M
Total Long-Term Assets	$156.2M	$156.9M	$155.3M
Total Assets	$461.9M	$460.3M	$458.1M
YoY Change	3.24%	3.5%	13.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.52M	$9.514M	$13.20M
YoY Change	-23.65%	-48.49%	-17.86%
Accrued Expenses	$21.20M	$20.00M	$17.40M
YoY Change	85.96%	68.07%	45.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$56.71M	$52.00M	$50.60M
YoY Change	13.01%	4.0%	9.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$55.50M	$55.80M	$56.30M
YoY Change	5.71%	8.77%	140.6%
Total Long-Term Liabilities	$55.50M	$55.80M	$56.30M
YoY Change	5.71%	8.77%	140.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.71M	$52.00M	$50.60M
Total Long-Term Liabilities	$55.50M	$55.80M	$56.30M
Total Liabilities	$112.2M	$107.8M	$107.0M
YoY Change	9.26%	6.1%	52.86%
SHAREHOLDERS EQUITY
Retained Earnings	$75.61M
YoY Change	-7.16%
Common Stock	$273.5M
YoY Change	3.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$349.6M	$352.5M	$351.1M
YoY Change
Total Liabilities & Shareholders Equity	$461.9M	$460.3M	$458.1M
YoY Change	3.24%	3.51%	13.45%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$5.121M	-$1.699M	$2.580M
YoY Change	272.44%	-124.76%	-74.61%
Depreciation, Depletion And Amortization	$4.930M	$4.710M	$4.480M
YoY Change	6.94%	28.34%	62.32%
Cash From Operating Activities	$16.19M	$6.750M	$13.53M
YoY Change	72.42%	-53.77%	-26.55%
INVESTING ACTIVITIES
Capital Expenditures	-$5.820M	-$6.010M	-$3.560M
YoY Change	433.94%	1838.71%	232.71%
Acquisitions
YoY Change
Other Investing Activities	-$12.71M	-$1.950M	-$4.490M
YoY Change	-139.06%	-97.34%	-172.54%
Cash From Investing Activities	-$18.52M	-$7.970M	-$8.050M
YoY Change	-158.89%	-89.18%	-257.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	90.00K	940.0K	60.00K
YoY Change	-90.82%	-29.32%	-64.71%
NET CHANGE
Cash From Operating Activities	16.19M	6.750M	13.53M
Cash From Investing Activities	-18.52M	-7.970M	-8.050M
Cash From Financing Activities	90.00K	940.0K	60.00K
Net Change In Cash	-2.240M	-280.0K	5.540M
YoY Change	-105.36%	-99.52%	-76.63%
FREE CASH FLOW
Cash From Operating Activities	$16.19M	$6.750M	$13.53M
Capital Expenditures	-$5.820M	-$6.010M	-$3.560M
Free Cash Flow	$22.01M	$12.76M	$17.09M
YoY Change	110.02%	-14.42%	-12.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22031410
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22031410
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2020	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2019	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2018	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M29D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M2D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y9M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y10M2D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M2D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M2D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y9M21D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y10M2D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M2D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y10M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y10M6D
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198037000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11057000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34325000
CY2019Q4	us-gaap	Inventory Net InventoryNet	35664000
CY2019Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	2976000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10160000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	292219000
CY2019Q4	ingn	Rental Equipment Net Of Allowances RentalEquipmentNetOfAllowances	39308000
CY2019Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9704000
CY2019Q4	ingn	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	7266000
CY2019Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1730000
CY2019Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4388000
CY2019	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	6253000
CY2018	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	7567000
CY2019	us-gaap	Gross Profit GrossProfit	171861000
CY2018	us-gaap	Gross Profit GrossProfit	178580000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	263252000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	81434000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-87000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	344621000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	447339000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	340546000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	336015000
CY2019	ingn	Rental Revenue Net RentalRevenueNet	21397000
CY2018	ingn	Rental Revenue Net RentalRevenueNet	22096000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9401000
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	95641000
CY2019	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	7289000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7029000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	31000
CY2019Q4	ingn	Land And Building LandAndBuilding	125000
CY2019Q4	ingn	Construction In Process ConstructionInProcess	1773000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64294000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	44856000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19438000
CY2019Q4	us-gaap	Goodwill Goodwill	32954000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77533000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8827000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5855000
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	14467000
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	14452000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2669000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4888000
CY2020Q4	us-gaap	Assets Assets	461852000
CY2019Q4	us-gaap	Assets Assets	447339000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33712000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30730000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7091000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6215000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	5740000
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	4923000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1931000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2014000
CY2020Q4	ingn	Contract With Customer Liability And Lease Deferred Revenue Current ContractWithCustomerLiabilityAndLeaseDeferredRevenueCurrent	6994000
CY2019Q4	ingn	Contract With Customer Liability And Lease Deferred Revenue Current ContractWithCustomerLiabilityAndLeaseDeferredRevenueCurrent	5478000
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1242000
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	821000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56710000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50181000
CY2020Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	8654000
CY2019Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	7648000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8078000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4702000
CY2020Q4	ingn	Earnout Liability Noncurrent EarnoutLiabilityNoncurrent	26940000
CY2019Q4	ingn	Earnout Liability Noncurrent EarnoutLiabilityNoncurrent	26559000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11822000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13541000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	25000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	87000
CY2020Q4	us-gaap	Liabilities Liabilities	112229000
CY2019Q4	us-gaap	Liabilities Liabilities	102718000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22131447
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22131447
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	273521000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	349623000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	75605000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	475000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	12790000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11595000
CY2020	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	5695000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461852000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	280189000
CY2020	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	123425000
CY2020	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	14755000
CY2020	us-gaap	Gross Profit GrossProfit	138180000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	909000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	4712000
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-1566000
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	981000
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	577000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	196634000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29717000
CY2018	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	2678000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	972000
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	351000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	9129000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21980326
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	227041000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12790000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2348000
CY2018	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1208000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	51845000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	452000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	310424000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9129000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2748000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8203000
CY2020	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	19000
CY2020	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	331000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	332000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	562000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	349623000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5829000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	20950000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	51845000
CY2020	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-864000
CY2019	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-568000
CY2018	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-1160000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	68000
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	416000
CY2019	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	17177000
CY2018	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	17518000
CY2019	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	2233000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2873000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1053000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	810000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16707000
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-928000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-31000
CY2020	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	2970000
CY2019	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	5856000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2296000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2064000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1626000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5830000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3202000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6360000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	870000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5188000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4538000
CY2020	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	1823000
CY2019	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	3041000
CY2018	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	3359000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-203000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2724000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3360000
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	319000
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	429000
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	64000
CY2020	ingn	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	3291000
CY2019	ingn	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6716000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-832000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	103000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	37013000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	40593000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	59977000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22751000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	58686000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	76162000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	14545000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	91350000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	63455000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	255000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	254000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4385000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3143000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8043000
CY2020	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	12957000
CY2019	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	3117000
CY2018	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	4580000
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	715000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	70401000
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	163000
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	194000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25640000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44057000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24965000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	332000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3109000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17156000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2084000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2748000
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2348000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	350000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	928000
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1208000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2066000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4929000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18296000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	486000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-62000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	373000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13925000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1403000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53681000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	198037000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	196634000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	142953000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	211962000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	198037000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-713000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	239000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1653000
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	25749000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	55000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	66000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	125000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since adopting the Company’s direct-to-consumer rental strategy in 2009, the Company has directly sold or rented more than 968,000 of its Inogen oxygen concentrators as of December 31, 2020. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, on April 13, 2017. On May 4, 2017, Inogen Europe Holding B.V. acquired all issued and outstanding capital stock of MedSupport Systems B.V. (MedSupport) and began operating under the name Inogen Europe B.V. The Company merged Inogen Europe Holding B.V. and Inogen Europe B.V. on December 28, 2018. Inogen Europe B.V. is the remaining legal entity. Inogen completed the acquisition of New Aera, Inc. (New Aera) on August 9, 2019.</p>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of long-lived assets, stock-based compensation expense, income taxes, fair value of acquired intangible assets and goodwill and fair value of earnout liabilities. Actual results could differ from these estimates.</p>
CY2020	ingn	Standard Warranty Period Offered StandardWarrantyPeriodOffered	P3Y
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	5258000
CY2019	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	8757000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5908000
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5903000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	280189000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	340546000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	336015000
CY2020Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2020	ingn	Rental Revenue Recognition New Accounting Pronouncement Timing RentalRevenueRecognitionNewAccountingPronouncementTiming	P30D
CY2020	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company generally provides a warranty against defects in material and workmanship. The Company provides a 3-year, 5-year or lifetime warranty on Inogen One systems sold and a 3-year and lifetime warranty on Inogen At Home systems sold. The Tidal Assist® Ventilator (TAV®) system has a 1-year and a 3-year warranty. The Company also offers a lifetime warranty for direct-to-consumer sales of its oxygen concentrators.
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	19257000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19257000
CY2020	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value of derivative instruments and hedging activities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company transacts business in foreign currencies and has international sales and expenses denominated in foreign currencies, subjecting the Company to foreign currency risk. The Company has entered into foreign currency forward contracts, generally with maturities of twelve months or less, to reduce the volatility of cash flows primarily related to forecasted revenue denominated in certain foreign currencies. These contracts allow the Company to sell Euros in exchange for U.S. dollars at specified contract rates. Forward contracts are used to hedge forecasted sales over specific months. Changes in the fair value of these forward contracts designed as cash flow hedges are recorded as a component of accumulated other comprehensive income within stockholders’ equity and are recognized in the consolidated statements of comprehensive income during the period which approximates the time the corresponding sales occur. The Company may also enter into foreign exchange contracts that are not designated as hedging instruments for financial accounting purposes. These contracts are generally entered into to offset the gains and losses on certain asset and liability balances until the expected time of repayment. Accordingly, any gains or losses resulting from changes in the fair value of the non-designated contracts are reported in other expense, net in the consolidated statements of comprehensive income. The gains and losses on these contracts generally offset the gains and losses associated with the underlying foreign currency-denominated balances, which are also reported in other income (expense), net.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records the assets or liabilities associated with derivative instruments and hedging activities at fair value based on Level 2 inputs in other current assets or other current liabilities, respectively, in the consolidated balance sheet. The Company had a related payable of $863 and $514 as of December 31, 2020 and 2019, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company documents the hedging relationship and its risk management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company assesses hedge effectiveness and ineffectiveness at a minimum quarterly but may assess it monthly. For derivative instruments that are designed and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported in other comprehensive income (loss) and reclassified into earnings in the same periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current period earnings.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will discontinue hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedge risk. The cash flow hedge is de-designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge. In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in the fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company will discontinue hedge accounting and recognize immediately in earnings gains and losses that were accumulated in other comprehensive income related to the hedging relationship.</p>
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	562000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-811000
CY2020	ingn	Preacquisition Loss Recoveries PreacquisitionLossRecoveries	672000
CY2019	ingn	Preacquisition Loss Recoveries PreacquisitionLossRecoveries	0
CY2020Q4	us-gaap	Cash Cash	52812000
CY2019Q4	us-gaap	Cash Cash	51560000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	159150000
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	146477000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211962000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198037000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19257000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11057000
CY2020Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	459000
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	590000
CY2020	ingn	Increase Decrease In Provisions For Bad Debt And Revenue Adjustments IncreaseDecreaseInProvisionsForBadDebtAndRevenueAdjustments	575000
CY2019	ingn	Increase Decrease In Provisions For Bad Debt And Revenue Adjustments IncreaseDecreaseInProvisionsForBadDebtAndRevenueAdjustments	611000
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	30907000
CY2020	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Gross HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableGross	1.000
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	36104000
CY2019	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Gross HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableGross	1.000
CY2020	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34325000
CY2019	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29717000
CY2020	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2020Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	22318000
CY2019Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	31676000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3743000
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5174000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1246000
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1186000
CY2020Q4	us-gaap	Inventory Net InventoryNet	24815000
CY2019Q4	us-gaap	Inventory Net InventoryNet	35664000
CY2020Q4	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	0
CY2020	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2527000
CY2019	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2854000
CY2018	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2289000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9577000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9674000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10030000
CY2020Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	575000
CY2019Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	395000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74024000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64294000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1779000
CY2019	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.049
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34325000
CY2019	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2020Q4	ingn	Doubtful Accounts DoubtfulAccounts	52000
CY2020	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.002
CY2019Q4	ingn	Doubtful Accounts DoubtfulAccounts	205000
CY2019	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.006
CY2020Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	396000
CY2020	ingn	Rental Revenue Adjustments Percentage RentalRevenueAdjustmentsPercentage	0.013
CY2019Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	411000
CY2019	ingn	Rental Revenue Adjustments Percentage RentalRevenueAdjustmentsPercentage	0.011
CY2020Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	742000
CY2020	ingn	Sales Returns Percentage SalesReturnsPercentage	0.024
CY2019Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	1163000
CY2019	ingn	Sales Returns Percentage SalesReturnsPercentage	0.032
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1190000
CY2020	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.039
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date. The Company has also </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hedging relationships with a single counterparty to offset the forecasted Euro</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based revenues. The credit risk has been reduced due to a net settlement arrangement whereby the Company </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is allowed to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> net settle transactions with a single net amount payable by one party to the other.</span></p>
CY2020	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.736
CY2019	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.702
CY2020	us-gaap	Revenues Revenues	308487000
CY2019	us-gaap	Revenues Revenues	361943000
CY2018	us-gaap	Revenues Revenues	358111000
CY2020	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1970000
CY2019	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1043000
CY2018	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1187000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45794000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	44856000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28230000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19438000
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.96
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.44
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.94
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.30
CY2018	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22514513
CY2018	us-gaap	Net Income Loss NetIncomeLoss	51845000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21980326
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21821104
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21266696
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21980326
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22241064
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22514513
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2020	us-gaap	Advertising Expense AdvertisingExpense	34180000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	40251000
CY2018	us-gaap	Advertising Expense AdvertisingExpense	30755000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5829000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	20950000
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	64471
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	419960
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1247817
CY2020	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22044797
CY2019	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22241064
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	45000
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	30742000
CY2019Q4	us-gaap	Goodwill Goodwill	32954000
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-211000
CY2020Q4	us-gaap	Goodwill Goodwill	33165000
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	760173
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	223193
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39330
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2018Q4	us-gaap	Goodwill Goodwill	2257000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15783000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	68797000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	84282000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6749000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77533000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9004000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4160000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1265000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	84580000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8746000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8423000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7847000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7831000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7784000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	28166000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	68797000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12520000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16399000
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9023000
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	11124000
CY2020Q4	ingn	Accrued Litigation Settlement Current AccruedLitigationSettlementCurrent	8000000
CY2020Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	2468000
CY2019Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	1675000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	449000
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	713000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1252000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	819000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33712000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30730000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4000
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	87000
CY2020Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	3796000
CY2019Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	3158000
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2642000
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2169000
CY2020Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	649000
CY2019Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	801000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7091000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6215000
CY2020	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	options to extend the leases for up to 5 years.
CY2020	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	2864000
CY2019	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	2288000
CY2018	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	1638000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2342000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	2486000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2622000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2269000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5237000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7855000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.033
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.038
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-74000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-330000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	198000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	136000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1931000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8078000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10009000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	2224000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	1897000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	1843000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	1534000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	576000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	3076000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11150000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1141000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10009000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-6464000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	22553000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	40245000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1184000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1719000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	210000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5280000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	24272000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	40455000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-40000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	381000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	560000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	171000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	505000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	366000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	131000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	309000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3497000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9774000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-193000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-396000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1630000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-72000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-145000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-117000
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	44000
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2956000
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-11521000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	549000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3322000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11390000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8346000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7981000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20145000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20087000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	1381000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	1984000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3379000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3257000
CY2020Q4	ingn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2427000
CY2019Q4	ingn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1627000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35678000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34936000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4805000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2961000
CY2020Q4	ingn	Deferred Tax Liabilities Intangible Amortization DeferredTaxLiabilitiesIntangibleAmortization	14292000
CY2019Q4	ingn	Deferred Tax Liabilities Intangible Amortization DeferredTaxLiabilitiesIntangibleAmortization	16192000
CY2020Q4	ingn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2139000
CY2019Q4	ingn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1418000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	21236000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20571000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	14442000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	14365000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0386
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0370
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0373
CY2020	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.1680
CY2019	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.0081
CY2018	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.4501
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0811
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0897
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0139
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0262
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0124
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0098
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1039
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1368
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.2815
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1932000
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1889000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1294000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1889000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1294000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1062000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	70000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	595000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	232000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	181000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	154000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1889000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1294000
CY2020	ingn	Voting Rights Associated With Each Share Of Common Stock VotingRightsAssociatedWithEachShareOfCommonStock	1
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2018	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2019	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1836426
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.77
CY2017	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	88.31
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	708319
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.22
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	771
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.24
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1127336
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.89
CY2018	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	89.28
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	851039
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	32.12
CY2018Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	92.05
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1109280
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	34.75
CY2018Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	89.42
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1127336
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.89
CY2018	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	89.28
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	109291
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	28.45
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	37161
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	44.58
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	980884
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.24
CY2019	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	34.07
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	929825
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	34.73
CY2019Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	34.64
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	977589
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	35.21
CY2019Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	34.11
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	980884
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.24
CY2019	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	34.07
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18626
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	17.81
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6779
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	48.23
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.49
CY2020	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	11.81
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	35.49
CY2020Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	11.81
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	35.49
CY2020Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	11.81
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	494000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7910000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	98743000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8203000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9129000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12790000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8203000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9129000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12790000
CY2020Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	457000
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	457000
CY2020Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	60200000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	12571000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9530000
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	6171000
CY2020	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	9462000
CY2019	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	8131000
CY2018	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	7693000
CY2020	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-754000
CY2019	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	1433000
CY2018	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	90000
CY2020	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	6885000
CY2019	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	6523000
CY2018	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4424000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14394000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	12571000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9530000
CY2019Q2	ingn	Number Of Lawsuits NumberOfLawsuits	2
CY2019Q4	ingn	Number Of Additional Shareholder Derivative Who Filed Lawsuits NumberOfAdditionalShareholderDerivativeWhoFiledLawsuits	3
CY2020Q1	ingn	Number Of Consolidated Shareholder Derivative Lawsuits NumberOfConsolidatedShareholderDerivativeLawsuits	4
CY2020Q2	ingn	Number Of Consolidated Shareholder Derivative Lawsuits NumberOfConsolidatedShareholderDerivativeLawsuits	2
CY2020Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	17
CY2020Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	0
CY2019Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	11
CY2019Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	1
CY2020Q1	us-gaap	Revenues Revenues	88489000
CY2020Q2	us-gaap	Revenues Revenues	71691000
CY2020Q3	us-gaap	Revenues Revenues	74329000
CY2020Q4	us-gaap	Revenues Revenues	73978000
CY2020Q1	us-gaap	Gross Profit GrossProfit	38366000
CY2020Q2	us-gaap	Gross Profit GrossProfit	32749000
CY2020Q3	us-gaap	Gross Profit GrossProfit	33006000
CY2020Q4	us-gaap	Gross Profit GrossProfit	34059000
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1687000
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3525000
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1913000
CY2020Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5205000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-98000
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	945000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-214000
CY2020Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-84000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1589000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	2580000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1699000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-5121000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21916365
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21963472
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21998299
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22042288
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21916365
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22221356
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21998299
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22042288
CY2019Q1	us-gaap	Revenues Revenues	90202000
CY2019Q2	us-gaap	Revenues Revenues	101063000
CY2019Q3	us-gaap	Revenues Revenues	91761000
CY2019Q4	us-gaap	Revenues Revenues	78917000
CY2019Q1	us-gaap	Gross Profit GrossProfit	44409000
CY2019Q2	us-gaap	Gross Profit GrossProfit	50215000
CY2019Q3	us-gaap	Gross Profit GrossProfit	43315000
CY2019Q4	us-gaap	Gross Profit GrossProfit	33922000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6072000
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13684000
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8753000
CY2019Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4237000
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	770000
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3524000
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1890000
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2862000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	5302000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	10160000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	6863000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-1375000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21750305
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21815634
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21840473
CY2019Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21878004
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22534885
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22359679
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22191688
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21878004

Files In Submission

Name	View Source	Status
0001564590-21-008106-index-headers.html	Edgar Link	pending
0001564590-21-008106-index.html	Edgar Link	pending
0001564590-21-008106.txt	Edgar Link	pending
0001564590-21-008106-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ggplubxherby000001.jpg	Edgar Link	pending
ggplubxherby000002.jpg	Edgar Link	pending
ingn-10k_20201231.htm	Edgar Link	pending
ingn-10k_20201231_htm.xml	Edgar Link	completed
ingn-20201231.xsd	Edgar Link	pending
ingn-20201231_cal.xml	Edgar Link	unprocessable
ingn-20201231_def.xml	Edgar Link	unprocessable
ingn-20201231_lab.xml	Edgar Link	unprocessable
ingn-20201231_pre.xml	Edgar Link	unprocessable
ingn-ex1039_698.htm	Edgar Link	pending
ingn-ex1040_167.htm	Edgar Link	pending
ingn-ex231_8.htm	Edgar Link	pending
ingn-ex311_6.htm	Edgar Link	pending
ingn-ex312_9.htm	Edgar Link	pending
ingn-ex321_7.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INGN
Inogen Inc Stock $ingn

2020 Q4 Form 10-K Financial Statement

#000156459021008106 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN Inogen Inc Stock $ingn

2020 Q4 Form 10-K Financial Statement

#000156459021008106 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN
Inogen Inc Stock $ingn